Revvity (NYSE:RVTY) Price Target Cut to $115.00 by Analysts at Barclays

Revvity (NYSE:RVTY) had its price target decreased by Barclays from $116.00 to $115.00 in a report issued on Friday, Benzinga reports. Barclays currently has an equal weight rating on the stock.

Other research analysts have also issued research reports about the stock. Jefferies Financial Group began coverage on shares of Revvity in a report on Monday, June 3rd. They issued a hold rating and a $115.00 price objective for the company. TD Cowen raised their price objective on shares of Revvity from $123.00 to $130.00 and gave the company a buy rating in a report on Tuesday, April 30th. Finally, Robert W. Baird raised their price objective on shares of Revvity from $126.00 to $127.00 and gave the company an outperform rating in a report on Tuesday, April 30th. Seven research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, Revvity has an average rating of Moderate Buy and an average price target of $118.69.

Revvity Trading Down 0.8 %

RVTY opened at $104.86 on Friday. The company’s 50 day moving average is $107.16 and its 200-day moving average is $106.19. Revvity has a 1-year low of $79.50 and a 1-year high of $131.96. The company has a current ratio of 2.23, a quick ratio of 1.92 and a debt-to-equity ratio of 0.40. The company has a market cap of $12.94 billion, a P/E ratio of 86.66, a PEG ratio of 2.72 and a beta of 1.08.

Revvity (NYSE:RVTY) last posted its quarterly earnings results on Monday, April 29th. The company reported $0.98 earnings per share for the quarter, beating analysts’ consensus estimates of $0.94 by $0.04. Revvity had a net margin of 5.49% and a return on equity of 7.37%. The company had revenue of $649.90 million for the quarter, compared to the consensus estimate of $646.83 million. During the same period last year, the company posted $1.01 EPS. The firm’s quarterly revenue was down 3.7% compared to the same quarter last year. Equities research analysts predict that Revvity will post 4.65 earnings per share for the current fiscal year.

Revvity Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, August 9th. Shareholders of record on Friday, July 19th will be issued a dividend of $0.07 per share. The ex-dividend date is Friday, July 19th. This represents a $0.28 annualized dividend and a yield of 0.27%. Revvity’s payout ratio is 23.14%.

Insiders Place Their Bets

In other Revvity news, insider Joel S. Goldberg sold 4,000 shares of the firm’s stock in a transaction that occurred on Friday, June 7th. The shares were sold at an average price of $110.46, for a total transaction of $441,840.00. Following the completion of the transaction, the insider now owns 36,900 shares in the company, valued at approximately $4,075,974. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 0.60% of the company’s stock.

Institutional Trading of Revvity

Several hedge funds have recently modified their holdings of RVTY. Parkside Financial Bank & Trust bought a new stake in shares of Revvity in the 4th quarter valued at $25,000. Gladius Capital Management LP increased its stake in shares of Revvity by 84.1% in the 3rd quarter. Gladius Capital Management LP now owns 232 shares of the company’s stock valued at $26,000 after acquiring an additional 106 shares in the last quarter. CENTRAL TRUST Co bought a new stake in shares of Revvity in the 4th quarter valued at $27,000. Benjamin F. Edwards & Company Inc. acquired a new stake in Revvity in the 4th quarter valued at $27,000. Finally, ORG Partners LLC acquired a new stake in Revvity in the 4th quarter valued at $32,000. Institutional investors own 86.65% of the company’s stock.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.